retatrutide for diabetes Promises Big Weight Loss, but Safety Remains a Question Retatrutide for weight loss: Study
Description
It is an investigational triple agonist (GLP-1, GIP, and glucagon receptors) not yet approved by the MHRA for use in the UK as of mid-2025
It can also be prescribed for those who are overweight, with a BMI of 27 or higher, if they also have at least one weight-related health condition
The research topics listed on this page describe areas of scientific investigation and should not be interpreted as medical advice, treatment guidance or claims of clinical benefit.
To maintain weight loss after stopping GLP-1, focus on a diet rich in protein and fiber to help you feel full and manage your appetite naturally
1 In what states do you prescribe compounded GLP-1 injections
Needle length for subcutaneous injection should be 12.7mm (1/2 inch) for most individuals
